SMARCB1 and meningioma: Importantly, when we screened our cohort of 110 primary, non-recurrent meningiomas (n=66 NF2 atypical, n=12 NF2 benign CNV-high, n=4 non-NF2 benign, CNV-high, n=12 NF2 benign CNV-low, n=12 non-NF2 benign CNV-low and n=4 NF2/SMARCB1), we did not identify any TERT promoter mutations (Supplementary Data 11).